key: cord-0893050-4hxqnb2e authors: Grupper, Ayelet; Rabinowich, Liane; Schwartz, Doron; Schwartz, Idit F.; Ben‐Yehoyada, Merav; Shashar, Moshe; Katchman, Eugene; Halperin, Tami; Turner, Dan; Goykhman, Yaacov; Shibolet, Oren; Levy, Sharon; Houri, Inbal; Baruch, Roni; Katchman, Helena title: Reduced humoral response to mRNA SARS‐CoV‐2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus date: 2021-05-07 journal: Am J Transplant DOI: 10.1111/ajt.16615 sha: 87495d9996e79cba6a664744755e9f2f113c228a doc_id: 893050 cord_uid: 4hxqnb2e COVID‐19 is associated with increased morbidity and mortality in transplant recipients. There are no efficacy data available regarding these patients with any of the available SARS‐CoV‐2 vaccines. We analyzed the humoral response following full vaccination with the BNT162b2 (Pfizer‐BioNTech) in 136 kidney transplant recipients, and compared it to 25 controls. In order to exclude prior exposure to the virus, only participants with negative serology to SARS‐CoV‐2 nucleocapsid protein were included. All controls developed a positive response to spike protein, while only 51 of 136 transplant recipients (37.5%) had positive serology (p < .001). Mean IgG anti‐spike level was higher in the controls (31.05 [41.8] vs. 200.5 [65.1] AU/mL, study vs. control, respectively, p < .001). Variables associated with null humoral response were older age (odds ratio 1.66 [95% confidence interval 1.17–2.69]), high‐dose corticosteroids in the last 12 months (1.3 [1.09–1.86]), maintenance with triple immunosuppression (1.43 [1.06–2.15]), and regimen that includes mycophenolate (1.47 [1.26–2.27]). There was a similar rate of side effects between controls and recipients, and no correlation was found between the presence of symptoms and seroconversion. Our findings suggest that most kidney transplant recipients remain at high risk for COVID‐19 despite vaccination. Further studies regarding possible measures to increase recipient's response to vaccination are required. COVID-19 is associated with increased morbidity and mortality in transplant recipients. There are no efficacy data available regarding these patients with any of the available SARS-CoV-2 vaccines. We analyzed the humoral response following full vaccination with the BNT162b2 (Pfizer-BioNTech) in 136 kidney transplant recipients, and compared it to 25 controls. In order to exclude prior exposure to the virus, only participants with negative serology to SARS-CoV-2 nucleocapsid protein were included. All controls developed a positive response to spike protein, while only 51 of 136 transplant recipients (37.5%) had positive serology (p < .001). Mean IgG anti-spike level was higher in the controls (31.05 [41.8] [1.26-2.27] ). There was a similar rate of side effects between controls and recipients, and no correlation was found between the presence of symptoms and seroconversion. Our findings suggest that most kidney transplant recipients remain at high risk for COVID-19 despite vaccination. Further studies regarding possible measures to increase recipient's response to vaccination are required. in solid organ transplant recipients is associated with increased morbidity and mortality due to comorbidities and immunosuppression state. 1, 2 Based on data from other vaccinations, the immune response of solid organ recipients to vaccination may be blunted, [3] [4] [5] and an adequate vaccine response cannot be assumed. Transplant recipients were not enrolled in phase 3 studies of SARS-CoV-2 vaccines, 6, 7 and currently no efficacy, immunogenicity, or safety data are available for this vulnerable population with any of the approved COVID-19 vaccines. Recently, in a study of 436 solid organ transplant recipients, the majority of participants did not mount appreciable immune response following a single dose of mRNA SARS-CoV-2 vaccine. 8 The present study was aimed, for the first time to the best of our knowledge, to quantify the humoral response following full vaccination with the BNT162b2 (Pfizer-BioNTech) SARS-CoV-2 vaccine, in a cohort of kidney transplant recipients, by determining the level of antibodies directed against the S (spike) antigen, comparing it to controls, and exploring the factors that may be associated with it. In order to eliminate prior exposure to the virus and evaluate the influence of the vaccine itself, only participants with negative serology to SARS-CoV-2 nucleocapsid protein were included. The study includes two cohorts: A study group, composed of adult kidney transplant recipients who are routinely followed in our transplant center clinic and were in a routine visit during the study period. The control group, composed of 25 health-care workers (none of them receiving immunosuppressive treatment) from our institution. All the participants provided written informed consent. The patients were included if they have completed the full vaccination and self-reported of no positive polymerase chain reaction (PCR) to SARS-CoV-2 before. All participants had been vaccinated with the BNT162b2 SARS-CoV-2 (Pfizer-BioNTech) vaccine, with the recommended dosing interval of 21 days between the two doses. The blood samples were collected between 10 and 20 days after the second vaccine dose injection. Freshly collected blood in clot activator and gel tube was centrifuged at 4500 rpm for 10 min. The sera were separated and stored at 4°C for analysis. LIAISON SARS-CoV-2 S1/S2 IgG chemiluminescent assay (DiaSorin S.p.A.) was used according to the manufacture instructions, to detect IgG antibodies directed against a recombinant S protein (S1/S2). 9 Samples displaying <12.0 AU/mL were considered negative, those ranging between 12.0 and 15.0 AU/mL are equivocal, and those >15 AU/mL were considered as positive. For the purpose of the analysis, participants with equivocal response (a total of two participants from the study group) were considered as negative. In addition, in order to explore prior exposure to SARS-CoV-2, every participant had a test to detect IgG antibodies directed against the SARS-CoV-2 nucleocapsid protein, performed with an Architect i2000SR analyzer (Abbot Diagnostics) and Abbott chemistry according to the manufacture instructions. A cutoff of 1.4 index (S/C) was used. 10 Exclusion criteria included a history of prior positive PCR test for SARS-CoV-2; detectable IgG antibodies for the SARS-CoV-2 nucleocapsid protein; and individuals who were not fully vaccinated or had less than 10 days following the second vaccine dose. Every participant was asked to report the side effects after each dose of the vaccine (during 7 days following every dose). The side effects were divided to local (pain, redness, swelling, and regional lymphadenopathy) and systemic side effects (fever, chills, headache, fatigue, myalgia, arthralgia, nausea and vomiting, diarrhea) and Clinical and epidemiological data were obtained from the medical charts. We used the records on the maintenance immunosuppression, as well as the baseline recorded laboratory tests that were routinely taken during the last clinic visit prior the first dose of vaccine and processed in the hospital central laboratory. Triple immunosuppression was defined as any combination of three different medications (including prednisone, CNIs, MMF, mTOR inhibitors, or azathioprine). Treatment with high-dose corticosteroids was defined as a pulse of methylprednisolone (≥125 mg), or prednisone ≥40 mg/day. Low-dose prednisone was defined as 5 mg/day. Estimated glomerular filtration rate (eGFR) was calculated using MDRD formula 12 and adjusted to body surface area (Mosteller calculation). Body mass index (BMI) was defined as dry weight in kilograms divided by height in square meters. The study was approved by the local ethical institutional review board. Continuous variables were first tested for normal distribution using the Kolmogorov-Smirnov test and Q-Q plots, and were summarized and displayed as mean (standard deviation, SD) for normally distributed variables, and as median (IQR, interquartile range) for nonnormally distributed variables. Categorical variables were displayed as number of patients and the percentage in each group. For all categorical variables, the chisquare statistic was used to assess the statistical significance between groups. Continuous variables were compared by using a t-test if normally distributed or by Kruskal-Wallis/Mann-Whitney test if nonnormally distributed. Correlation between two continuous parameters was calculated by Spearman analysis. In order to identify which variables are affected by multicollinearity and the strength of the correlation, we calculated variance inflation factors (VIF) and reported VIF above 3. We fitted binary logistic regression models for the risk of negative serology test including the significant variables that were found in univariate analysis. The control group was composed of 25 participants. One hun- Unfortunately, one kidney transplant recipient, who had undetectable antibody levels after full vaccination, expired due to se- (Figure 2) . A moderate multicollinearity (VIF = 9.3) for MMF and triple immunosuppression regimen was found. In the control group, we found a trend of inverse correlation between age and antibody levels (correlation coefficient = −0.27, p= .084); however, it did not reach statistical significance. Organ transplant recipients exhibit worse outcome from SARS-CoV-2 infection, due to comorbidities and immunosuppression. 13, 14 Accordingly, an effective and safe vaccination against SARS-CoV-2 is 16 In our cohorts, in accordance with that, most common side effect was mild local pain, without major adverse events. We could not find any correlation of the vaccine side effects or their severity to humoral response, or any difference in the side effects between controls and kidney transplant recipients. Despite a theoretical concern that vaccination may trigger organ rejection, 17 The most significant predictors of failure to mount a humoral response in our cohort of kidney transplant recipients were advanced age, need for high-dose corticosteroids during the last (prevaccination) year, maintenance with three immunosuppressive medications, and a regimen that includes MMF. Some association between advanced age and positive but lower antibody response was found in immunocompetent patients after COVID-19, 30 as well as after mRNA SARS-CoV-2 vaccination. 31, 32 Our finding indicates that even in immunosuppressed patients age may be an independent predictor of poor immunological response. In our control group, there was an inverse trend of age and antibody level; however, it was not statistically significant. Similarly, MMF has a well-known suppressive effect on the immune system, including the inhibition of antibody production. 37, 38 Our finding of a significant decrease in vaccination response in kidney recipients on MMF treatment is in line with previous reports, which demonstrated a dose-related correlation of MMF with decreased influenza and cholera vaccine responsiveness in renal transplant subjects. 28, [39] [40] [41] [42] We could not find an independent association between vaccine humoral immune response and treatment with antithymocyte globulin during the prevaccination year. Although the small number of participants who received this treatment preclude us from a valid conclusion, these findings are in agreement with result of influenza vaccination studies, which failed to show a significant relation between induction immunosuppression and vaccine immunogenicity. 43−45 Our study demonstrated that the serological response to vaccination was related to the net burden of immunosuppression: the greater the degree of immunosuppression, the less likely the patient will respond to immunization (OR 1.43 for triple vs double immunosuppressive regimens). This finding is not only clinically obvious, but also supported by previous studies that found an increased risk to poor seroprotection 46 Optimal timing may be important in maximizing the response to immunization following solid organ transplantation. It is common to wait at least 3 and often up to 12 months after transplantation before giving vaccines, once maintenance immunosuppression levels have been attained, 48, 49 in order to maximize the likelihood of developing a protective immune response. In our study, patients shortly after transplantation demonstrated reduced immune response rate, but this correlation was not an independent predictor when high-dose steroids were included into analysis. This finding emphasizes the need for an individual approach to transplanted patients' immunization; while specific timing may vary based on individual circumstance, we should try to vaccinate when the effect of any immunosuppressive agents is at its nadir. 48, 49 Strengths of this study include its novelty. It is the first published data about full SARS-CoV-2 vaccine in kidney transplant recipients. The exclusion of participants with IgG antibodies to nucleocapsid protein eliminates the possibility of humoral response to the former virus exposure and validates our results. Limitations of the study include a relatively small sample size, with a nonmatched control group. Short follow-up period and absence of assessing the cellular immune response preclude us to address full The authors of this manuscript have no conflicts of interest to disclose as described by the American Journal of Transplantation. The data that support the findings of this study are available from the corresponding author upon reasonable request. Ayelet Grupper https://orcid.org/0000-0002-5590-9428 An initial report from the French SOT COVID Registry suggests high mortality due to COVID-19 in recipients of kidney transplants Is COVID-19 infection more severe in kidney transplant recipients? Serologic vaccination response after solid organ transplantation: a systematic review Immune responsiveness and protective immunity after transplantation Solid organ transplantation and response to vaccination Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccines Immunogenicity of a single dose of SARS-CoV-2 messenger RNA vaccine in solid organ transplant recipients Side-by-side comparison of three fully automated SARS-CoV-2 antibody assays with a focus on specificity Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of diet in renal disease study group COVID-19 and kidney transplantation: results from the TANGO International Transplant Consortium COVID-19 infection in kidney transplant recipients at the epicenter of pandemics First month of COVID-19 vaccine safety monitoring-United States Safety of the first dose of SARS-CoV-2 vaccination in solid organ transplant recipients Update on immunizations in solid organ transplant recipients: what clinicians need to know Safety of influenza vaccine in heart transplant recipients Safety of live vaccinations on immunosuppressive therapy in patients with immune-mediated inflammatory diseases, solid organ transplantation or after bone-marrow transplantation -A systematic review of randomized trials, observational studies and case reports Humoral and cellular immune responses after influenza vaccination in kidney transplant recipients Does vaccination in solid-organ transplant recipients result in adverse immunologic sequelae? A systematic review and meta-analysis Outcomes associated with influenza vaccination in the first year after kidney transplantation Influenza vaccination is efficacious and safe in renal transplant recipients Safety and immunogenicity of two RNA-based COVID-19 vaccine candidates Differential immune response to influenza and pneumococcal vaccination in immunosuppressed patients after heart transplantation Immunogenicity of pneumococcal vaccine in renal transplant recipients-three year follow-up of a randomized trial Hepatitis B vaccination results in 140 liver transplant recipients A prospective, comparative study of the immune response to inactivated influenza vaccine in pediatric liver transplant recipients and their healthy siblings A longitudinal study of SARS-CoV-2-infected patients reveals a high correlation between neutralizing antibodies and COVID-19 severity Sex, age and hospitalization drive antibody response in a COVID-19 convalescent plasma donor population COVID-19 vaccine race: analysis of age-dependent immune responses against SARS-CoV-2 indicates that more than just one strategy may be needed Safety and immunogenicity of SAR-CoV-2 mRNA vaccine in older adults Serum antibody response to influenza vaccine in pulmonary patients receiving corticosteroids Influenza vaccination in patients with rheumatic diseases Serum antibody response to pneumococcal vaccine in children with nephrotic syndrome Vaccines and disease-modifying antirheumatic drugs: practical implications for the rheumatologist Suppression of the humoral immune response by mycophenolate mofetil Immune Responsiveness in renal transplant recipients: mycophenolic acid severely depresses humoral immunity in vivo Influenza vaccine after pediatric kidney transplant: a Midwest Pediatric Nephrology Consortium study Impact of immunosuppression on recall immune responses to influenza vaccination in stable renal transplant recipients Comparison of the immunogenicity of Dukoral® oral cholera vaccine between renal transplant recipients on either a calcineurin inhibitor or mycophenolate -A controlled trial Response of transplant recipients to influenza vaccination based on type of immunosuppression: a meta-analysis Impact of anti-T-cell therapy in the immunogenicity of seasonal influenza vaccine in kidney transplant recipients T-cell and B-cell immune responses to seasonal influenza vaccine in solid organ transplant recipients receiving anti-T cell therapies Influenza vaccination in the organ transplant recipient: review and summary recommendations Poor seroprotection but allosensitization after adjuvanted pandemic influenza H1N1 vaccine in kidney transplant recipients A comparison of triple therapy with double therapy immunosuppression in cadaveric renal transplantation IDSA clinical practice guideline for vaccination of the immunocompromised host Vaccination of solid organ transplant candidates and recipients: Guidelines from the American society of transplantation infectious diseases community of practice